Real‐World Efficacy and Safety of Sintilimab‐Based Regimens against Advanced Esophageal Cancer: A Single‐Center Retrospective Observational Study

作者：Chenyu Wang, Linzhi Jin, Xinyu Cheng, Runchuan Ren, Anping Zheng, Anlin Hao, Nengchao Wang, Jinwen Zhang, Fuyou Zhou, Yaowen Zhang · 发表于：BioMed Research International · 年份：2022 · DOI：10.1155/2022/7331687 · 被引用次数：7 · 研究领域：Cancer Immunotherapy and Biomarkers、Esophageal Cancer Research and Treatment、Lung Cancer Treatments and Mutations

This study is aimed at assessing the sintilimab‐based regimens’ safety and efficacy for advanced esophageal cancer (EC) treatment in the real world. Cases of advanced EC treated with sintilimab‐based regimens in the Anyang Tumor Hospital between 1 January 2020 and 1 August 2021 were retrospectively examined. Progression‐free survival (PFS), overall survival (OS), disease control rate (DCR), objective response rate (ORR), and adverse events (AEs) were evaluated. Among the 50 included patients, the median PFS was 11.3 months (95% CI: 5.0‐17.6 months), and the 1‐year PFS rate was 49.2%. The median OS was not reached, and the 1‐year OS rate was 67.1%. Complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) were seen in 14% ( n = 7), 46% ( n = 23), 32% ( n = 16), and 8% ( n = 4) of the 50 patients, respectively. Therefore, the ORR and DCR were 60% (30/50) and 92% (46/50), respectively. The CR rate of patients with radiotherapy was higher than that without radiotherapy (25% vs. 3.8%, P = 0.031). The 1‐year OS rate was higher in patients with radiotherapy than in patients without radiotherapy (85.9% vs. 53.2%, P = 0.020). The most observed AEs included anemia, decrease in white blood cell count, nausea/vomiting, and hypoproteinemia. Sintilimab‐based regimens achieved good disease control and tolerance for treating advanced EC in the real world. Combined radiotherapy can improve the efficacy and deserves further study.